Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment
British Journal of Dermatology · 24.08.2023 · 189 (3) · 339-341
DOI: 10.1093/bjd/ljad149 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Dermatology, online erschienen am 04.05.2023. Verfasst von William D Shipman und 5 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Dermatology. Hauptthemen laut MEDLINE: Pemphigoid, Bullous. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, Colton Center for Autoimmunity at Yale.
Abstract (Originalsprache)
Immune checkpoint inhibitor-induced bullous pemphigoid (ICI-BP) is a clinically debilitating immune-related adverse event in need of novel therapeutic approaches, as conventional treatment can counteract intended tumour immunity. Here we demonstrate that interleukin (IL)-4 and IL-13 expression is elevated in ICI-BP similar to conventional autoimmune BP, and further demonstrate partial and complete disease clearance with dupilumab in four patients with ICI-BP. These data indicate that IL-4Rα inhibition may be a promising new therapy for ICI-BP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Departments of Dermatology.
- Pathology, Yale University School of Medicine, New Haven, CT, USA.
ORCID-Profile: Jeffrey M Cohen, William Damsky, Mary M Tomayko
Förderung
- NIAMS NIH HHS
- Colton Center for Autoimmunity at Yale
Zitieren
APA
Shipman, W. D., Singh, K., Cohen, J. M., Leventhal, J., Damsky, W., & Tomayko, M. M. (2023). Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment. British Journal of Dermatology, 189(3), 339-341. https://doi.org/10.1093/bjd/ljad149
Vancouver
Shipman WD, Singh K, Cohen JM, Leventhal J, Damsky W, Tomayko MM. Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment. British Journal of Dermatology. 2023;189(3):339-341. doi:10.1093/bjd/ljad149
BibTeX
@article{Shipman2023,
author = {Shipman, William D and Singh, Katelyn and Cohen, Jeffrey M and Leventhal, Jonathan and Damsky, William and Tomayko, Mary M},
title = {Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment},
journal = {British Journal of Dermatology},
year = {2023},
volume = {189},
number = {3},
pages = {339--341},
doi = {10.1093/bjd/ljad149}
}
EUVIMED